Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Adenosine (ADO) is generated from ATP by CD39 and CD73 ectonucleotidases.
• ADO signaling through G protein-coupled receptors can suppress anti-tumor immune responses, including CD8+ T cell and natural killer cell activity.
• The ADO pathway is implicated in tumor immune surveillance, particularly in non-solid cancers.

Purpose of the Study:

• To review the role of adenosine in cancer immunotherapy.
• To discuss the mechanisms of ADO signaling in cancer immune responses.
• To highlight the potential of targeting ADO signaling for gastric cancer treatment.

Main Methods:

• Literature review of recent studies on adenosine in cancer immunotherapy.
• Analysis of the mechanisms underlying ADO signaling in immune responses.
• Evaluation of current and emerging therapeutic strategies targeting the ADO pathway.

Main Results:

• Adenosine suppresses anti-tumor immunity by inhibiting immune cell infiltration and function.
• The ADO pathway plays a significant role in tumor immune evasion.
• Early-phase studies of ADO pathway inhibitors in gastric cancer show encouraging results.

Conclusions:

• Targeting adenosine signaling represents a promising strategy for enhancing cancer immunotherapy.
• Further research into ADO pathway mechanisms can inform the development of novel cancer treatments.
• The ADO pathway holds potential for treating gastric cancer and other malignancies.